1.45
Camp 4 Therapeutics Corp stock is traded at $1.45, with a volume of 135.40K.
It is down -4.61% in the last 24 hours and down -26.77% over the past month.
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
See More
Previous Close:
$1.52
Open:
$1.59
24h Volume:
135.40K
Relative Volume:
0.51
Market Cap:
$33.26M
Revenue:
$264.74M
Net Income/Loss:
$-49.71M
P/E Ratio:
-0.354
EPS:
-4.0959
Net Cash Flow:
$-43.55M
1W Performance:
-7.64%
1M Performance:
-26.77%
6M Performance:
-72.22%
1Y Performance:
+262.50%
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
617-651-8867
Address
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CAMP
Camp 4 Therapeutics Corp
|
1.45 | 33.26M | 264.74M | -49.71M | -43.55M | -4.0959 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-27-25 | Initiated | Wedbush | Outperform |
Nov-05-24 | Initiated | JP Morgan | Overweight |
Nov-05-24 | Initiated | Piper Sandler | Overweight |
Nov-05-24 | Initiated | William Blair | Outperform |
Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
Sep-24-21 | Reiterated | Craig Hallum | Buy |
Jun-25-21 | Reiterated | Craig Hallum | Buy |
Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
Mar-05-20 | Reiterated | Craig Hallum | Buy |
Dec-20-19 | Reiterated | Craig Hallum | Buy |
Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
May-29-19 | Downgrade | Goldman | Neutral → Sell |
May-01-19 | Reiterated | Craig Hallum | Buy |
Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
Dec-14-18 | Reiterated | B. Riley FBR | Buy |
Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
Nov-27-18 | Initiated | Goldman | Neutral |
Oct-15-18 | Initiated | Jefferies | Hold |
Sep-28-18 | Reiterated | Craig Hallum | Hold |
Apr-27-18 | Reiterated | Craig Hallum | Hold |
Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
Albany Ninja Lab Announces 2025 Summer Camp Programs - Yahoo Finance
CAMP4 Elects Directors and Ratifies Auditor - TipRanks
Calamp Corp : CalAmp to Present at Needham & Company 9th Annual Growth Stock Conference - marketscreener.com
CalAmp Corp. Announces CEO Changes, Effective January 22, 2024 - marketscreener.com
CalAmp Corp. Announces the Appointment of Paul Washicko as the New Senior Vice President of Product Management - marketscreener.com
Pre-market Movers: NIVF, TRAW, KKR, AGEN... - RTTNews
CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Wedbush sets CAMP4 stock at Outperform, $8 price target - Investing.com Australia
Wedbush sets CAMP4 stock at Outperform, $8 price target By Investing.com - Investing.com UK
Wedbush Initiates CAMP4 Therapeutics at Outperform With $8 Price Target - marketscreener.com
Parent's Night Out (6 months to 23 months) - Bucks County Herald newspaper
The Call EventsMount Saint Charles Middle School Field Hockey Clinic - woonsocketcall.com
ALT5 Sigma Corporation Announces Record Date for Alyea Therapeutics Corporation Transaction - The Joplin Globe
The Manufacturers Life Insurance Company Buys 3,095 Shares of Camping World Holdings, Inc. (NYSE:CWH) - Defense World
Therapeutic horseback riding facility hosts camp night for veterans, first responders - WSBT
CAMP4 Therapeutics Unveils Promising Data at ASGCT 2025 - TipRanks
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th - The Manila Times
CAMP4 Therapeutics Reports Positive Results in SYNGAP1-Related Disorders and Urea Cycle Disorders at ASGCT Annual Meeting - Nasdaq
CAMP4 Clinical Data Shows 50% Protein Boost in Primate Brain Study | CAMP Stock News - Stock Titan
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
CAMP4 Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating - TipRanks
CAMP4 Reports First Quarter 2025 Financial Results And Corporate Highlights - marketscreener.com
CAMP4 Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Nasdaq
CAMP4 Clinical Trials Hit Major Milestone: Q1 Earnings Show Strong Pipeline Progress in Rare Disease Treatment - Stock Titan
Prediction: Nvidia Just Received Its First Wall Street Sell Rating -- and More Will Follow After May 28 - The Globe and Mail
Northeast Ohio Parent Camp and Summer Programs Guide 2025 - Northeast Ohio Parent
Jesse Dee - UnionLeader.com
Sranan Gold Announces Positive Engagement with the Local Community, a Major Stakeholder at the Tapanahony Project in Suriname - Yahoo Finance
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
14-year-old dies by suicide at Weaverville mental health program run by owner of shuttered Trails Carolina - Asheville Watchdog
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Pre-market Movers: KTTA, SXTC, GLMD, TCMD... - RTTNews
New Ulcerative Colitis Drug PALI-2108 Outperforms Standard Treatments in Crucial Disease Models - Stock Titan
Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Barrick Gold Trading Cheaper Than Industry: Time to Buy the Stock? - The Globe and Mail
Daily Times Chronicle EventsBoy Scout Troop 42 Pancake Breakfast - Homenewshere.com
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting - The Manila Times
CAMP4 Therapeutics to Present Preclinical and Phase 1 Clinical Trial Data at 28th Annual Meeting of the American Society of Gene and Cell Therapy - Nasdaq
Revolutionary RNA Therapy Shows Promise: CAMP4 Unveils First Human Trial Data at Gene Therapy Conference - Stock Titan
Where's Plumpy'Nut? A lifesaving food for malnourished kids is caught up in U.S. cuts - NPR
Global School of Chess Announces 100 Full-Scholarship Seats for New Inclusivity & Awareness Camp - Yahoo Finance
Home | Department of Parks and Recreation - City and County of Honolulu (.gov)
Machine Learning-Assisted Spectroscopy Ensures Safety of Cell Therapy | Research & Technology | Apr 2025 - Photonics Spectra
Where Will Rigetti Computing Be in 10 Years? - The Globe and Mail
Programmable Therapeutics Restore Gene Expression - Mirage News
Restoring healthy gene expression with programmable therapeutics - MIT News
10 Barrel Brewing Co. and Scout Campers Unveil Camp Coldie: The Ultimate Adventure Beer - The Globe and Mail
Explorer Finds Major Gold Structure in Ontario Camp - streetwisereports.com
Top 3 Health Care Stocks Poised for Big Gains in Q2 - NewsBreak: Local News & Alerts
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2 - Benzinga
Camp Sunrise returns for young kids dealing with grief; Teen Grief Retreat added - Central Oregon Daily
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Camp 4 Therapeutics Corp Stock (CAMP) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
AH Equity Partners Bio I, L.L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
727,272 |
7,999,992 |
1,579,885 |
Enavate Sciences GP, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
1,363,636 |
14,999,996 |
3,785,802 |
Polaris Management Co. VII, L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
909,090 |
5AM Partners VI, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
2,625,145 |
Nashat Amir | Director |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
909,090 |
Schwab Andrew J. | Director |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
2,625,145 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):